Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Barclays PLC raised its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 433.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,222 shares of the company’s stock after acquiring an additional 56,244 shares during the period. Barclays PLC owned approximately 0.15% of Y-mAbs Therapeutics worth $910,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. State Street Corp increased its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after buying an additional 47,846 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. SG Americas Securities LLC purchased a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $178,000. Finally, Squarepoint Ops LLC lifted its stake in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares in the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $6.33 on Wednesday. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.01 and a 12 month high of $20.90. The firm has a market capitalization of $283.51 million, a PE ratio of -11.72 and a beta of 0.69. The business’s fifty day moving average price is $10.15 and its 200 day moving average price is $12.09.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the company posted ($0.18) EPS. As a group, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.66 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on YMAB shares. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.